Showing results (171-180 of 183) with videos related to
Sort By:
Pageof 19
Neurology|May 22, 1998
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, N A Simonian, J A Alam, et al.JAMA|April 20, 2026
Using Serious Games to Increase the Implementation of Trauma Triage Guidelines: A Randomized Clinical TrialDeepika Mohan, Chung-Chou H Chang, Baruch Fischhoff, et al.Neurology|July 21, 2010
Rapid disease course in African Americans with multiple sclerosisI Kister, E Chamot, J H Bacon, et al.Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.Neurology|March 31, 2012
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS studyE Waubant, D Pelletier, M Mass, et al.Neurology|April 18, 2007
Natalizumab reduces visual loss in patients with relapsing multiple sclerosisL J Balcer, S L Galetta, P A Calabresi, et al.Proceedings of the National Academy of Sciences of the United States of America|December 12, 2022
Enhanced stability and clinical absorption of a form of encapsulated vitamin A for food fortificationWen Tang, Jia Zhuang, Aaron C Anselmo, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 27, 2016
Extended interval dosing of natalizumab in multiple sclerosisL Zhovtis Ryerson, T C Frohman, J Foley, et al.Journal of the Neurological Sciences|March 22, 2017
Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric populationTheresa Bourne, Michael Waltz, T C Casper, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 20, 2003
Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis ConsortiumB Weinstock-Guttman, L D Jacobs, C M Brownscheidle, et al.Pageof 19